Stock comparison
Corcept Therapeutics
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.01B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$20.85B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 69B | MTD |
| Benjamin Graham | 86C | 64C | CORT |
| Philip Fisher | 64C | 62C | CORT |
| Peter Lynch | 32F | 66B | MTD |
| Joel Greenblatt | 47D | 66B | MTD |
| Charlie Munger | 60C | 73B | MTD |
| Terry Smith | 68C | 70B | MTD |
Side-by-side metrics
| Metric | CORT | MTD |
|---|---|---|
| Market cap | $6.01B | $20.85B |
| P/E (TTM) | 122.0x | 23.9x |
| EV/EBIT | 131.9x | 20.6x |
| ROIC (TTM) | -1.23% | 36.09% |
| Gross margin | 98.25% | 57.79% |
| Net margin | 6.23% | 21.4% |
| Revenue CAGR 5y | 20.1% | 2.01% |
| EPS CAGR 5y | -0.52% | 6.12% |
| Debt / Equity | 0.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Revenue CAGR 5y20.1%vs 2.01%+90%
- Gross margin98.25%vs 57.79%+41%
MTD leads on
- EPS CAGR 5y6.12%vs -0.52%+108%
- ROIC (TTM)36.09%vs -1.23%+103%
- Debt / Equity-vs 0.0x+100%
- EV/EBIT20.6xvs 131.9x+84%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.